You can view 5 more pages before signing in

Proton pump inhibitors (PPIs) in liver cirrhosis

Last edited 27 May 2022. Last reviewed 11 Sept 2023

Proton pump inhibitors in liver cirrhosis

Mahmud et al undertook a study to evaluate the association between PPI (proton pump inhibitor) exposure and all-cause mortality, infection, and decompensation in cirrhotic patents
- PPI exposure is associated with increased risk of infection and decompensation in cirrhosis, which may mediate liver-related mortality
- however, PPI use was associated with reduced all-cause mortality in those with prior gastrointestinal bleeding, suggesting benefit in the presence of an appropriate indication
results from Mahmud et al overall show that "..exposure to PPIs, although it may be related to a greater risk of decompensation and infection, can have a protective effect in terms of survival if prescribed according to appropriate indications. Interestingly, the daily dose and the cumulative dose of PPIs exposure assume a key role in assessing the outcomes of cirrhotic patients. Therefore, as recommended elsewhere, PPIs should only be prescribed where appropriate and at the minimum dose necessary for an adequate effect..." (2)

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

Proton pump inhibitors (PPIs) in liver cirrhosis

Related pages

Create an account to add page annotations